Form 4: Citius Pharmaceuticals CEO Leonard Mazur Amends Warrant, Acquires Additional Derivative Securities

Sentiment:

SEC Form 4 5 April 2024 4:05 PM

📋All filings for Citius Pharmaceuticals, INC

CEO Leonard Mazur amended a warrant and acquired additional derivative securities in Citius Pharmaceuticals, according to a recent SEC Form 4 filing.

Summary

On April 3, 2024, Leonard L. Mazur, CEO of Citius Pharmaceuticals, engaged in transactions involving derivative securities.
Mazur amended an existing warrant to extend its termination date from April 5, 2024, to April 5, 2025, effectively canceling the old warrant and issuing a replacement.
The exercise price for the warrants is $1.42.
Mazur holds a total of 10,255,343 shares of common stock directly.
He also holds various stock options with exercise prices ranging from $0.67 to $6.75 and expiration dates between 2024 and 2033.
The total number of shares underlying these options is 3,365,000.
Additionally, Mazur holds warrants to purchase common stock with exercise prices of $0.77 and $1.15, expiring in 2024, and warrants with an exercise price of $1.42 expiring in 2025.
These warrants cover a total of 6,537,003 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions by a company insider. The warrant amendment could be seen as slightly positive, but it's a routine disclosure.

Positives

The extension of the warrant expiration date provides Mazur with more time to potentially exercise the warrant and acquire additional shares.

Risks

The exercise of warrants and options by Mazur could potentially dilute existing shareholders' equity.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

The warrant amendment and potential exercise of options could dilute existing shareholders' equity.

Key Dates

Date	Description
04/03/2019	Original issue date of the warrant that was amended.
09/12/2017	Date options vested in full.
09/13/2020	Date options vested in full.
09/04/2021	Date options vested in full.
07/22/2021	Date options were granted.
10/11/2021	Date options were granted.
10/08/2022	Date options vested in full.
10/04/2022	Date options were granted.
10/06/2023	Date options vested in full.
10/10/2023	Date options were granted.
09/27/2024	Expiration date of warrant to purchase common stock.
08/14/2024	Expiration date of warrant to purchase common stock.
09/12/2024	Expiration date of stock options.
04/05/2024	Original termination date of the warrant that was amended.
04/03/2024	Date of warrant amendment and derivative security transactions.
04/05/2025	New termination date of the amended warrant.
09/13/2027	Expiration date of stock options.
09/04/2028	Expiration date of stock options.
10/08/2029	Expiration date of stock options.
10/06/2030	Expiration date of stock options.
07/22/2031	Expiration date of stock options.
10/11/2031	Expiration date of stock options.
10/04/2032	Expiration date of stock options.
10/10/2033	Expiration date of stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.